文献速递甲状腺核医学核素与放射性配体治疗

BRAFV600E突变对无已知远处转移的甲状腺乳头状癌患者放射性碘治疗疗效无显著影响

BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases.
PubMed 文献 · Clin Nucl Med · 2018-01-01

这项回顾性研究纳入2012年1月至2016年3月接受甲状腺全切除术加淋巴结清扫、放射性碘治疗和促甲状腺激素抑制治疗的甲状腺乳头状癌患者,按BRAF突变状态分两组。中位随访37个月,BRAF突变与性别、肿瘤大小和甲状腺外侵犯相关,但与初始风险分层及放射性碘治疗的临床反应无显著差异。结论提示BRAF突变状态可能不影响无远处转移患者的放射性碘治疗临床反应。

要点

  • BRAF突变与性别、肿瘤大小和甲状腺外侵犯相关,与其他临床病理特征无显著关联。
  • BRAF突变阳性与阴性组初始风险分层无显著差异(P=0.845)。
  • 全部患者及高复发风险患者中,两组放射性碘治疗临床反应均无显著差异(P=0.586和P=0.680)。

核心结论

  • BRAF突变状态可能不影响无远处转移的甲状腺乳头状癌患者对放射性碘治疗的临床反应。

研究设计与样本

  • 回顾性研究,纳入2012年1月至2016年3月接受甲状腺全切除术加淋巴结清扫、放射性碘治疗和促甲状腺激素抑制治疗的甲状腺乳头状癌患者,按BRAF突变状态分为2组。
  • 共纳入512例无远处转移的甲状腺乳头状癌患者,其中BRAF突变阳性338例,中位随访37个月。

主要发现

  • BRAF突变与性别、肿瘤大小和甲状腺外侵犯相关,与其他临床病理特征无显著关联。
  • BRAF突变阳性组与阴性组初始风险分层无显著差异(P=0.845)。
  • 随访结束时,全部患者中两组放射性碘治疗临床反应无显著差异(P=0.586)。
  • 高复发风险患者中两组放射性碘治疗临床反应无显著差异(P=0.680)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The BRAF mutation is the most common and specific oncogenic event in papillary thyroid carcinoma (PTC). However, its role in radioiodine therapy decision making has yet to be established. This study aimed to evaluate the impact of the BRAF mutation on the clinical response to radioiodine therapy. METHODS: This retrospective study included PTC patients who received total thyroidectomy with lymph node dissection, radioiodine therapy, and thyroid-stimulating hormone suppression between January 2012 and March 2016. Included patients were divided into 2 groups based on the BRAF mutation status. The association between the clinicopathological characteristics and the BRAF mutation was evaluated. After a median follow-up of 37 months, the clinical outcome between these 2 groups was also compared based on the ongoing risk stratification. RESULTS: A total of 512 PTC patients without distant metastases were included, with a positive BRAF mutation in 338 patients. No significant association was observed between the BRAF mutation and clinicopathological characteristics, except for sex, tumor size, and extrathyroidal extension. The initial risk stratification between the positive and negative mutation groups revealed no significant difference (P = 0.845). At the end of follow-up, no significant difference regarding the clinical response to radioiodine therapy was demonstrated between these 2 groups for all patients or patients with high recurrence risk (P = 0.586 and P = 0.680, respectively). CONCLUSIONS: The BRAF mutation status may not impact the clinical response to radioiodine therapy for PTC patients without distant metastases.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Shen G, Kou Y, Liu B, et al. BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases. Clin Nucl Med. 2018. PMID: 29762246. doi:10.1097/RLU.0000000000002142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。